Health by Design
World’s first personal dosing app incorporating nutraceuticals, electroceutics and natural therapeutic technologies
World’s first personal dosing app incorporating nutraceuticals, electroceutics and natural therapeutic technologies
Information provided are based on evidence gathered from medical literature and clinical trials. Using medical history, symptoms, genetics, and lifestyle data, the system generates personalized treatment options.
The idōs App revolutionizes personalized and precision medicine. By offering access to a wide range of medical and health data, idōs empowers patients to take control of their health and make more informed decisions. Our App combines the processes of a Clinical Decision Support System (CDSS) with Translational Science, enabling us to provide innovative multiphasic dose layering methodologies tailored to each patient's specific needs. This is done through a combination of artificial intelligence, machine learning, and predictive analytics. The AI algorithms use patient data to make accurate predictions about the best treatment options and dosage levels for each individual. This allows us to provide personalized and precision care that reduces the risks of adverse events and maximizes the patient's chances of achieving the best possible outcomes.
The idōs App is designed to provide personalized and precise recommendations based on the user's unique health profile. By leveraging the power of AI and the vast knowledge derived from the NIH National Library of Medicine, we can deliver a comprehensive approach to health and well-being. Users can have confidence in the accuracy and reliability of our App, as it continuously updates its knowledge base with the latest scientific research and medical advancements.
The idōs App acts as a virtual healthcare companion providing users with a pinpoint geological area health risk analysis defining health impact factors in their current environment. Almost instantaneously, the system computes evidence-based recommendations derived from the comprehensive analysis of medical literature, clinical trials, and patient data. Additionally, through the CDSS component, it evaluates a wide range of factors, including medical history, symptoms, genetics, and lifestyle, to generate personalized treatment options. Translational Science further enhances this process by translating scientific research into practical, actionable insights.
At idōs, our system incorporates metadata from multiple substantiated resources such as for one example including all the twenty-seven Institutes of the National Library of Medicine by which we apply their scientific data and research. Our App utilizes advanced AI algorithms to analyze this information, allowing us to map the most effective formulations for specific health concerns. By incorporating the principles of personalized medicine, we can precisely tailor treatments to an individual's unique health profile optimizing their journey towards a better "Quality of Life".
idos, LLC.
Las Vegas, Nevada, United States of America
© 2024 idōs, LLc. All Rights Reserved.
This website complies with the Certified American Disabilities Act and Web Content Accessibility Guidelines 2.0 (WCAG 2.0)
These statements have not been evaluated by the Food and Drug Administration. Cannabinoids, vitamins, minerals, dietary supplements and nutraceutical products that are mentioned on this web site is not intended to diagnose, treat, cure, or prevent any disease. Always speak with your doctor for professional advice.
This website further uses cookies. By continuing to use this site, you accept and understand the FDA Disclosure and the use of cookies.
The medical information on this site is provided as an information resource only. This information is not intended to be patient education, nor does it create any patient-physician relationship, and should not be used as a substitute for professional diagnosis and treatment. Contact your certified Physician for any health issues you may have. These statements have not been evaluated by the FDA.